Expert Interviews

Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma
January 24, 2022

In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.

Key Takeaways: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 24, 2022

Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.

Apalutamide in Patients With mCSPC: Safety
January 24, 2022

GU oncologists discuss toxicities from androgen deprivation therapy and apalutamide as reported in the phase 3 TITAN study.

Poll Test
January 23, 2022

Multiple myeloma experts share background for discussion of the recent publication, “Survival benefit of ixazomib, lenalidomide and dexamethasone [IRD] over lenalidomide and dexamethasone [Rd] in relapsed and refractory multiple myeloma patients in routine clinical practice.”

Zev A. Wainberg, MD, on Findings From the Updated KEYNOTE-062 Trial With Pembrolizumab/Chemo for Advanced Gastric/GEJ Adenocarcinoma
January 21, 2022

In an interview with CancerNetwork® during the 2022 Gastrointestinal Cancer Symposium, Zev A. Wainberg, MD, discussed key updates from the phase 3 KEYNOTE-062 trial, examining pembrolizumab plus or minus chemotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma.

Quadruplet Regimens for Transplant-Eligible Multiple Myeloma
January 21, 2022

Implications of updated data from the GRIFFIN trial, in terms of using quadruplet therapy to manage patients with newly diagnosed multiple myeloma who are eligible for transplant.

Frontline Treatment for Transplant-Eligible Multiple Myeloma
January 21, 2022

An overview of doublet and triplet regimens used as first-line therapy for patients with newly diagnosed multiple myeloma who are eligible for transplant.

Transplant Eligibility Criteria in Multiple Myeloma
January 21, 2022

Impressions of the case of a 51-year-old man with newly diagnosed multiple myeloma and considerations that impact candidacy for an autologous stem cell transplant.

Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASH
January 20, 2022

Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.

Presentation: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 20, 2022

Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.